Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder-Reference-Cited by-同舟云学术

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

Published:2016-03-11 Issue:7 Volume:56 Page:806-815
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Laffont Celine M.¹,Gomeni Roberto²,Heidbreder Christian¹,Jones J. P.¹,Nasser Azmi F.¹

Affiliation:

1. Indivior Inc; Richmond; VA USA

2. R&D Department; Pharmacometrica; Longcol La Fouillade France

Funder

Indivior Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Arrested on heroin: a national opportunity;Boutwell;J Opioid Manag,2007

2. Centers for Disease Control and Prevention Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention 2004

3. Drug injectors sharing cookers and cotton increase their risk of hepatitis C;Thomas;NIDA Notes,2001

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products;Journal of Substance Use and Addiction Treatment;2024-07

2. Dynamics of clinical and laboratory indicators in patients with diabetic nephropathy caused by arterial hypertension after complex recovery treatment;Fizioterapevt (Physiotherapist);2024-05-11

3. Buprenorphine for Chronic Pain Management: a Narrative Review;Current Pain and Headache Reports;2023-10-28

4. Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder;Clinical Pharmacokinetics;2023-08-16

5. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids;Journal of Addiction Medicine;2023-07-28